Xiaobin Wu
Independent Non-Executive DirectorDr. Xiaobin Wu, Ph.D., was Chief Operating Officer at BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) since April 01, 2021 until January 1, 2026. Dr. Wu joined the BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) in April 2018. Dr. Wu Independent Non-Executive Director at Clover Biopharmaceuticals, Ltd. since September 26, 2021. Dr. Wu has experience in the pharmaceutical industry, including certain years leading China operations of multinational companies, with expertise in integrated research and development, strategy, commercialization and general management. Dr. Wu was President of BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) since May 2018 until January 1, 2026 and also served as its General Manager of China since May 2018 until January 1, 2026. Before joining BeiGene, Dr. Wu served as the country Manager of Pfizer China; and regional President of Pfizer Essential Health in Greater China Region from October 2009 to April 2018. Dr. Wu led Pfizer China business with focus and integrity, building an incredible business and establishing a strong culture of compliance. Under his leadership, Pfizer China experienced a significant growth, developed a clear vision and strategy, which transformed the business and organization to new heights and established its position as a leading multinational pharmaceutical company in China, also became a significant contributor to China?s healthcare system. Dr. Wu is widely recognized as an industry opinion leader in China, he actively worked with industry associations, helped to shape and influence the environment to ensure Chinese patients have access to high-quality medicines and vaccines. Prior to Pfizer, Dr. Wu served as President and Managing Director of Wyeth China and Hong Kong from 2004 to 2009. Before joining Wyeth, Dr. Wu served as the General Manager of Bayer Healthcare in China from 2001 to 2004. He started his career in 1992 in sales & marketing, also in Headquarters? functions with Bayer in Germany. Dr. Wu was elected as the Vice Chairman of China Pharmaceutical industry Research and Development Association since 2019. He is also a research fellow at Research Center of National Drug Policy and Ecosystem. In addition to his duties in industrial associations, Dr. Wu is frequently awarded with industry awards, including being voted as ?Person of the Year? in Healthy China Award 2017 and having won the award of ?2017 Top 10 Most Influential Person in Chinese Healthcare Industry? and ?2017 Social Responsibility Eminent Person Award.? Dr. Wu obtained Ph.D. in biochemistry and pharmacology in April 1993 and a master?s degree in molecular biology in January 1990 from the University of Konstanz in Germany.
Positions
- Company NameClover Biopharmaceuticals, Ltd.Stock Code02197PositionIndependent Non-Executive DirectorColleagues
- PLPeng LiangFounder, Chief Scientific Officer & Chairman of the Board
- JGJoshua G. LiangCEO & Executive Director
- YLYang LiChief Technology Officer
- HHHtay Htay HanChief Medical Officer of Vaccine
- BMBerry MichaelChief Technical Operation Officer
- TEThomas Edward LeggettIndependent Non-Executive Director
- XWXiaodong WangNon-Executive Director
